Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from April 2022.
aducanumab
-
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy -
Read more: Monthly Round-Up of What to Read on Pharma Law and Policy Monthly Round-Up of What to Read on Pharma Law and Policy
Topics range from issues related to FDA’s approval of aducanumab, to an analysis of the communication of survival data in cancer drug labels.
-
Read more: FDA Approves Aducanumab for Alzheimer’s Disease: An Unethical Decision? FDA Approves Aducanumab for Alzheimer’s Disease: An Unethical Decision?
FDA’s approval of aducanumab may run against the bioethical principles of beneficence and non-maleficence.
-
Read more: Aducanumab: A Bitter Pill to Swallow Aducanumab: A Bitter Pill to Swallow
Patients are understandably desperate, but their needs are best served by following the science, rather than lowering the standards for drugs.
